Loading
A count of 1.15 million US breast cancers from 2010 to 2014 in which Black women had 2.27 times the odds of a triple-negative diagnosis and women under 40 nearly twice the odds, confirming the disparity at national scale.
Scott, Mobley, Kuo and Il'yasova examined differences between triple-negative and other breast cancers by age, race and ethnicity and stage in the United States Cancer Statistics database. Of 1,151,724 breast cancers identified from 2010 through 2014, the triple-negative phenotype accounted for about 8.4 percent. In unadjusted analyses non-Hispanic Black women (odds ratio 2.27, 95 percent confidence interval 2.23 to 2.31) and Hispanic women (1.22, 1.19 to 1.25) had higher odds of a triple-negative diagnosis than non-Hispanic white women; women under 40 had the highest odds compared with women aged 50 to 64 (1.95, 1.90 to 2.01); stage III (1.69) and stage IV (1.47) at diagnosis conferred higher odds. Results varied slightly after adjustment.
The most recent national figure behind the statement that Black women in the United States have about twice the incidence of triple-negative breast cancer; trial enrolment has not matched it.
Shares Ethnicity-stratified outcome reporting for triple-negative breast cancer in NHS cancer statistics, Close the gap between who gets triple-negative breast cancer and who is in its trials, Trials do not represent the people who get cancer, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem and the tag tnbc-evidence.
Shares Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry, Close the gap between who gets triple-negative breast cancer and who is in its trials, Trials do not represent the people who get cancer, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem and the tag tnbc-evidence.
Shares Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares Close the gap between who gets triple-negative breast cancer and who is in its trials, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.